Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Aug 20.
Published in final edited form as: ACS Chem Biol. 2026 Aug 21;21(8):1897–1905. doi: 10.1021/acschembio.6c00052

Molecular Determinants of Ribosome Binding for the Antimicrobial Peptide Pdi1

Trevor T Dean a, Alyah Ziyad a, Dorota Klepacki a,b, José A Villegas a, Terry W Moore a,*
PMCID: PMC13489556  NIHMSID: NIHMS2198849  PMID: 42490145

Abstract

Type II proline-rich antimicrobial peptides have emerged as promising therapeutic candidates due to their ability to inhibit a previously undrugged stage of bacterial protein synthesis: translation termination. The recent characterization of the potent Type II proline-rich antimicrobial peptide, Pdi1, suggests it may represent a promising therapeutic candidate; however, no information is available concerning its ribosome-binding activity. The lack of biochemical and biophysical assays to interrogate the binding affinities and mechanism of action of this class of peptides presents a bottleneck in the drug-discovery pipeline. In this study, we report the first characterization of the ribosome-binding kinetics of a Type II proline-rich antimicrobial peptide, for which we applied a biolayer interferometry assay to study the Pdi1-ribosome interaction. Our results reveal slow dissociation kinetics, which indicates prolonged residence time in the ribosomal nascent peptide exit tunnel. Additionally, alanine scanning of the Pdi1 C-terminus revealed that specific residues are critical for ribosome binding and contribute to the rate of Pdi1 dissociation. These findings were validated in cell-based assays where alanine substitutions at these positions reduced antibiotic activity. We also demonstrated that a Pdi1 derivative which lacks the third-to-last pharmacophoric residue fails to inhibit translation termination, despite retaining a sub-micromolar minimum inhibitory concentration. These results demonstrate that select residues in the Pdi1 pharmacophore play a critical role in ribosome binding and dissociation, in addition to inhibiting translation termination.

Graphical Abstract

graphic file with name nihms-2198849-f0006.webp

Introduction

Antibiotics represent one of the major medical advancements of the 20th century; however, their over-prescription has rapidly resulted in microbial tolerance and waning efficacy.1 Antibiotic resistance represents a major threat to global health, as bacterial infections resistant to commonly prescribed antibiotics have been identified at an alarming rate.2,3 This problem is further compounded by the identification of multi-drug-resistant bacterial infections for which treatment options are limited.4,5 As a result, the identification of novel antibiotic compounds with unique mechanisms of action that can evade existing antibiotic resistance mechanisms is crucial. Recently, Type II proline-rich antimicrobial peptides (PrAMPs), a class of non-lytic antibiotic peptides, have demonstrated a novel bactericidal mechanism by inhibiting prokaryotic translation at the termination stage.6,7

Many Type II PrAMPs have been found in insects, where they are involved in the innate immune response to bacterial infections.8 These peptides are taken up by Gram-negative bacteria that contain the SbmA antibiotic transporter within their inner membrane.9 The antimicrobial activity of PrAMPs is a result of their ability to inhibit bacterial protein synthesis by binding the nascent peptide exit tunnel (NPET) of the ribosome.6 Type II PrAMPs are unique and distinct from Type I PrAMPs in that they inhibit translation termination through stabilization of the translation termination complex.6 The translation termination complex is composed of the ribosome, P-site tRNA, and a Release Factor (RF), which facilitates hydrolysis of the nascent peptide from the P-site tRNA. In some Gram-negative bacteria, the number of RFs is far fewer than the number of ribosomes.10 Thus, type II PrAMPs are thought to sequester RFs and deplete the cellular supply of this critical enzyme, resulting in dysregulated translation and ineffective translation termination. This inhibition of translation termination represents a novel antimicrobial paradigm and suggests that type II PrAMPs may be repurposed as a therapeutic strategy to combat drug-resistant pathogens.7

The first Type II PrAMP identified was Apidaecin 1b (Api1b), and medicinal chemists have performed extensive structure-activity relationship (SAR) studies in an attempt to generate therapeutically relevant drug candidates.11–13 These SAR efforts have been effective in generating derivatives, such as Api137, that have improved potencies and pharmacological profiles.12,13 Unfortunately, it is not clear that any of the analogs synthesized to date could show success in the clinic. Promisingly, recent efforts have identified and quantified the antibiotic potential of Type II PrAMPs from a wide range of insect species that also demonstrate inhibition of translation termination; some of these PrAMPs display a greater potency than ApiIb.7 These peptides share a conserved C-terminal ‘PHPRL’ motif, which is known to be critical for their mechanism of action and is considered the antibiotic pharmacophore.7,14 Among the known Type II PrAMPs, a peptide identified from Pimpla disparis, Pdi1 (Table 1), represents one of the most promising candidates for future SAR exploration.

Table 1:

Sequences of Pdil and Alanine Scan Derivatives

Peptide Sequence Molecular Weight (Da) Isoelectric Point Net Charge
Pdi1 H-GKPNRPRPAPIQPRPPHPRL-OH 2281.7 12.48 5
Pdi1(R14A) H-GKPNRPRPAPIQPAPPHPRL-OH 2196.59 12.3 4
Pdi1(P15A) H-GKPNRPRPAPIQPRAPHPRL-OH 2255.67 12.48 5
Pdi1(P16A) H-GKPNRPRPAPIQPRPAHPRL-OH 2255.67 12.48 5
Pdi1(H17A) H-GKPNRPRPAPIQPRPPAPRL-OH 2215.64 12.3 5
Pdi1(P18A) H-GKPNRPRPAPIQPRPPHARL-OH 2255.67 12.48 5
Pdi1(R19A) H-GKPNRPRPAPIQPRPPHPAL-OH 2196.59 12.3 5
Pdi1(L20A) H-GKPNRPRPAPIQPRPPHPRA-OH 2239.62 12.48 4
Scrambled Pdi1 H-PPIRPRQRPKPPLPHNPRAG-OH 2281.7 12.48 5

Despite the promise of these antimicrobial peptides, little is known about the molecular determinants that influence their affinity for the ribosome due to the lack of biophysical approaches to inform SAR studies. The most common approach relies on fluorescence anisotropy with ribosome and a fluorophore-labeled peptide, but very high ribosome concentrations are required. Here, we use biolayer interferometry (BLI) to find the association and dissociation rates governing a Type II PrAMP /ribosome interaction. We measured a picomolar dissociation constant between a surface-bound Pdi1 and the ribosome. Alanine scanning of the Pdi1 pharmacophore revealed that mutation of residues Arg14, Pro18 and Arg19 results in an increased dissociation rate, while other substitutions were moderately tolerated. These findings were validated in cell-based assays using drop diffusion and liquid broth microdilutions assays, which demonstrate that the dissociation rate of Pdi1 is a critical determinant of antibiotic activity. Cell-based assays also revealed that alanine substitution of residue His17 significantly reduces translation termination inhibition despite retention of a sub-micromolar minimum inhibitory concentration (MIC). Ribosome stalling experiments confirmed the loss of translation-termination inhibition for Pdi1(H17A); moreover, chemical modifications on reporter peptides introduced for performing fluorescence anisotropy and BLI did not affect their ability to inhibit translation termination. Our results suggest that BLI may serve as a novel, resource-conservative approach to screen synthetic derivatives of Pdi1 to characterize their ribosome-binding affinity and kinetics.

Methods/Experimental Section

Peptide Synthesis

Peptides were synthesized using a Liberty Lite (CEM corporation) automated peptide synthesizer. Amino acids were dissolved to a concentration of 0.2 M in N,N-dimethylformamide (DMF). A 500 mM solution of diisopropylcarbodiimide in DMF was prepared as a coupling agent, and a 500 mM solution of OxymaPure in DMF was used as a coupling additive to minimize racemization.15 Fmoc deprotection was carried out using 20% piperidine in DMF. Amino acid coupling was performed at each position twice. Peptides were synthesized using either Fmoc-Ala-Wang resin (0.21 mmol/g), Fmoc-Gly-Wang resin (0.70 mmol/g), or Fmoc-Leu-Wang resin (0.22 mmol/g).

Preparation of Fluorescently Labeled Pdi1 Peptide

For this application, a β-alanine residue was appended to the Pdi1 N-terminus following standard peptide coupling procedures; β-alanine is used to avoid Edman degradation.16 2 eq (relative to scale of peptide synthesis) of fluorescein 5-isothiocyanate (FITC, TCI Chemicals) and 1 eq of diisopropylethylamine (TCI Chemicals) were dissolved in 1 mL of DMF. Synthesized peptides covalently bound to Wang resin were added to the basic FITC solution and left to agitate overnight. Resin was washed with 3 column-volumes (CVs) of DMF, followed by 3 CVs of dichloromethane (DCM), and dried under air. Resin was stored at 4 °C until ready for use.

Peptide Cleavage Protocol

Peptides were cleaved from resin with a cocktail of 5% (w/v) phenol, 2% (v/v) triisopropylsilane, 5% (v/v) water, and 88% (v/v) trifluoroacetic acid under agitation for 2 hours. Peptides were precipitated with cold diethyl ether and pelleted via tabletop centrifugation. Peptide pellets were air dried and dissolved in water for subsequent purification or immediately used for downstream BLI testing.

Peptide Purification

Crude peptides were purified via semi-preparative HPLC using a Shimadzu LC-20AB pump (solvent system MeCN:H2O supplemented with 0.1% trifluoroacetic acid; 0 – 4 min, 10% MeCN; 4 – 20 min, 10 – 95% MeCN; 20 – 24 min, 95% MeCN; 24 – 27 min, 10% MeCN. Column: Aapptec Protein 5 μm C8, 300 Å, 0.78 × 250 cm). Fractions containing pure peptide were pooled and lyophilized. Lyophilized peptides were weighed and stored at −20 °C before use in downstream applications.

Peptide purity was assessed via analytical HPLC using a Shimadzu LC-20AB pump (solvent system MeCN:H2O supplemented with 0.1% trifluoroacetic acid; 0 – 1 min, 10% MeCN; 1 – 18 min, 10 – 95% MeCN; 18 – 21 min, 95% MeCN; 21 – 25 min, 10% MeCN. Column: Ascentis 5 μm C8, 300 Å, 0.46 × 25 cm). The identity of the purified peptides was confirmed using m/z data collected with a Bruker MALDI-TOF spectrometer.

Ribosome Production

This purification method was adapted from previous ribosome preparation approaches.17 Rosetta BL21 cells were grown in 500 mL of lysogeny broth (LB) supplemented with 30 μg/mL of chloramphenicol at 37 °C to an optical density of 0.1 Abs. Cells were pelleted by centrifugation and stored at −80 °C until ready for use. Cells were resuspended in suspension buffer (10 mM HEPES-KOH pH 7.6, 50 mM KCl, 10 mM Mg(OAc)2, and 7 mM β-mercaptoethanol) and lysed via sonication for 3 minutes (20% amplitude, 10 sec pulse-on, and 20 sec pulse-off). Bacterial lysate was centrifuged at 20000 × g (Sorvall SS-34 rotor) for 30 minutes and the resulting supernatant was supplemented with (NH4)2SO4 to a final concentration of 1.5 M. Supplemented lysate was centrifuged again at 20000 × g (Sorvall SS-34 rotor) for 30 minutes, and the resulting supernatant was filtered through a 0.45 μm membrane. Filtered supernatant was applied to a 5 mL HiTrap Butyl FF column (Cytiva) pre-equilibrated with buffer A (20 mM HEPES-KOH pH 7.6, 1.5 M (NH4)2SO4, 10 mM Mg(OAc)2, and 7 mM β-mercaptoethanol). The column was washed with 4:1 buffer A:buffer B (20 mM HEPES-KOH pH 7.6, 10 mM Mg(OAc)2, and 7 mM β-mercaptoethanol), and ribosomes were eluted with 1:1 buffer A:buffer B. Ribosome eluates were overlayed onto an equal volume of sucrose cushion buffer (20 mM HEPES-KOH pH 7.6, 10 mM Mg(OAc)2, 30 mM NH4Cl, 30% sucrose, and 7 mM β-mercaptoethanol) and centrifuged at 154000 × g(SW41Ti rotor) for 16 hours. The ribosome pellet was dissolved in ribosome buffer (20 mM HEPES-KOH pH 7.6, 30 mM KCl, 6 mM Mg(OAc)2, and 7 mM β-mercaptoethanol) and stored at −80 °C. Ribosome concentration was determined by light absorbance based on previously published findings that 1 Abs260nm = 28 nM.18,19

Fluorescence Anisotropy Assays

Ribosome fractions from multiple purifications were combined and concentrated using a centrifugal concentrator (Amicon Ultra Centrifugal Filter, Millipore Sigma). Concentrated ribosome solution was then split into two stock concentrations (23.2 μM and 15.6 μM) from which 2× serial dilutions were prepared (to 180 nM and 120 nM respectively). To a 384-well plate, 10 μL of ribosome was added to 10 μL of 20 nM FITC-Pdi1. The 384-well plate was left to incubate for 90 min at room temperature (25 °C) in the dark. Fluorescence anisotropy was then measured in triplicate using a Biotek Synergy Neo2 plate reader (λEx = 485 nm, λEm = 535 nm). This assay was performed twice in triplicate.

Competition experiments were performed using two ten-fold serial dilution series of the unlabeled peptide from 100 μM to 10 pM in ribosome buffer (10 μL). Ribosome solution was added (5 μL), and the plate was incubated for 60 min at room temperature (25 °C) in the dark. FITC-labeled peptide was added (5 μL) such that the final concentration of ribosome and FITC-labeled peptide was 750 nM and 20 nM, respectively. The plate was left to incubate for 90 min at room temperature (25 °C) in the dark. Fluorescence anisotropy was then measured in triplicate using a Biotek Synergy Neo2 plate reader (λEx = 485 nm, λEm = 535 nm). This assay was performed twice in triplicate.

Preparation of Biolayer Interferometry Reporter Peptides

5 eq (relative to scale of peptide synthesis) of biotin-PEG24-NHS ester (Broadpharm) were dissolved in a minimal volume of DMF and diluted in 100 mM aqueous NaHCO3. Synthesized peptides covalently bound to Wang resin were added to the basic biotin-PEG24-NHS ester solution and left to agitate overnight. Resin was washed with 3 CVs of DMF, followed by 3 CVs of DCM, and dried under air. Resin was stored at 4 °C until ready for use.

Biolayer Interferometry Kinetics Assay

Peptide pellets were dissolved in 2× BLI kinetics running buffer (ribosome buffer supplemented with 0.2% bovine serum albumin, 0.2% PEG-4000 and 0.05% Tween-20) and diluted to an appropriate concentration for loading to streptavidin-coated biosensors (250 μM to 5 μM). Ribosome samples were prepared at a concentration of 1 nM in 1× BLI kinetics running buffer (ribosome buffer supplemented with 0.1% bovine serum albumin, 0.1% PEG-4000 and 0.025% Tween-20) and 2× serially diluted to 31.3 pM. A 5 M NaCl solution was generated for the regeneration condition and 1× BLI kinetics running buffer was used as the neutralization condition. Briefly, biotinylated peptides were loaded onto the biosensor surface upon exposure to the peptide solution for 30 seconds. Binding measurements followed an iterative protocol where a baseline was established by exposing biosensors to 1× kinetics running buffer for 2 minutes. Biosensors were then exposed to the ribosome solution for 3 minutes, followed by exposure to 1× BLI kinetics running buffer for 3 minutes. Biosensors were regenerated for subsequent concentration series by exposure to regeneration solution for 5 seconds followed by a 5 second incubation with neutralization solution (×3). BLI measurements were performed using an Octet R2 (Sartorius) instrument. This assay was performed in triplicate.

Drop Diffusion and Stop Codon Readthrough Assay

Bacterial cells, Escherichia coli strain BL21 transformed with the pRXG (UGA) reporter plasmid,11 were grown overnight in lysogeny broth (LB) medium at 37 °C with shaking. An overnight culture was diluted 100-fold into fresh LB medium and grown at 37 °C with shaking until cell density reached A600 ~ 0.8. Culture (3 mL) was poured onto M9 medium/agar plates, supplemented with 50 μg/mL kanamycin, 0.2% glucose and 0.2mM IPTG. Excess liquid was aspirated, and plates were allowed to dry. 2 μL of 2 mM peptide solutions were applied to the plate surface. The plates were incubated at 37 °C for 16 h and imaged.

Liquid Broth Microdilution Assay

The minimum inhibitory concentrations (MICs) of Pdi1 peptides were determined by a microbroth dilution technique in 96-well plates. Specifically, exponentially growing E. coli BL21 cells were diluted to the final density OD600 = 0.002 in 33% Tryptic Soy Broth13 and 100 μL of the diluted culture were placed in each well. After the addition of the peptide, plates were incubated overnight at 37 °C. The minimal concentration of the peptide preventing the appearance of the visible cell density was recorded as the MIC.

Toeprinting Assay

Toeprinting experiments were conducted following a previously established procedure.5 Briefly, the DNA templates containing the modified and truncated E. coli yrbA gene ending with the TAG stop codon were expressed in the PURExpress cell-free transcription–translation system (New England Biolabs).20 The location of the stalled ribosome was determined by reverse transcriptase-catalyzed extension of the NV1 primer (GGTTATAATGAATTTTGCTTATTAAC). The reaction products were resolved in 6% sequencing gels alongside with the sequencing reactions. Relevant peptides were tested twice.

Results

Evaluation of Pdi1 Binding Affinity

Recent genome mining and antibiotic studies have identified Pdi1 (Table 1) as a potent Type II PrAMP with termination-inhibition activity and suggest it may serve as a promising scaffold for the development of therapeutically relevant analogs.7 To build upon these microbiological and biochemical studies, we sought to study the Pdi1 –ribosome interaction in vitro using a biophysical approach.

To date, the sole biophysical approach used to measure PrAMP binding affinity for the bacterial ribosome is fluorescence anisotropy; 19,21 however, this technique requires large amounts of ribosome to generate binding curves. We performed fluorescence anisotropy using fluorescein-labelled Pdi1 (FITC-Pdi1) titrated with increasing concentrations of purified E. coli ribosome.19,21 Our results demonstrate a concentration-dependent increase in fluorescence anisotropy with increasing concentrations of ribosome (Figure 1); however, binding saturation was not achieved, despite using ribosome concentrations that exceeded 10 μM. As an alternate approach, we performed a competition-based experiment similar to previous reports. In this competition experiment, unlabeled Pdi1 was titrated to outcompete FITC-Pdi1 to determine an IC50.22 The results from these experiments were inconclusive based on the dynamic range of the assay when using a maximal ribosome concentration of 750 nM (Figure S1). Because of the lack of binding saturation and the significant efforts required to prepare and purify such large quantities of ribosomes, we determined that fluorescence anisotropy was inefficient for screening Pdi1 analogs.

Figure 1: Assessment of FITC-Pdi1 Ribosome Binding In Vitro via Fluorescence Anisotropy.

Figure 1:

Binding of FITC-Pdi1 to purified ribosome. Assay was performed using a constant conentration of 20 nM FITC-Pdi1 and ribosome concentrations of 11.6 μM, 7.8 μM, 5.8 μM, 3.9 μM, 2.9 μM, 1.9 μM, 1.5 μM, 970 nM, 730 nM, 490 nM, 360 nM, 240 nM, 180 nM and 120 nM. Error bars represent the standard error of the mean for triplicate data. This assay was performed twice in triplicate.

Antibiotic – ribosome residence time is correlated with antibacterial outcomes,23,24 and a long residence time is an assumption of the translation termination inhibition model of Pdi1 activity; however, no kinetic binding data have been reported for Type II PrAMPs. Biolayer Interferometry (BLI), which has the ability to rapidly assess the binding affinities and kinetics, is an effective technique for measuring interactions between the E.coli ribosome and two of its known binding partners, E. coli initiation factor 2 and P. falciparum translation enhancing factor.25 This inspired us to design a BLI assay to assess the binding affinity and kinetics of the Pdi1 – ribosome interaction (Figure 2).

Figure 2: Graphical Representation of Pdi1 Ribosome Biolayer Interferometry Assay.

Figure 2:

(Top) Graphical representation of biolayer interferometry experiment. Biotinylated-Pdi1 associates with streptavidin-coated biosensor. Biosensors are then exposed to increasing concentrations of ribosome (analyte) to measure concentration-dependent increase in binding response. Ribosome-bound Pdi1 is then exposed to a buffer condition to measure the dissociation of analyte. (Bottom) Staggered overlay of example Pdi1- ribosome binding sensorgrams. Sensorgram colors reflect the expected profile of different ribosome concentrations.

The design of the reporter peptides for BLI was informed by the cryo-electron microscopy structure of Api137 bound to the translation termination complex in the NPET (PDB: 5O2R).6 The electron micrograph reveals that Api137 is buried deep within the ribosomal NPET with the peptide N-terminus > 50 Å away from the aperture. To account for this length, we designed N-terminally biotinylated Pdi1 reporter peptides that contain a 24-unit poly-ethylene glycol (PEG) linker which separates the biotin moiety from the peptide N-terminus. This PEG-linker length was selected based on atomic force microscopy measurements which suggest that a single PEG unit has a mean length of 2.8 Å;26 therefore, our linker length is predicted to be ~ 67 Å, which should be sufficient for the biotin moiety to extend outside the aperture of the NPET. Reporter peptides were generated in a single reaction where resin-bound peptides composed of chemically protected amino acids were exposed to NHS-PEG24-biotin in a 100 mM aqueous NaHCO3 solution (pH 8.0) for 16 hrs (Figure S2). With this approach, the capacity for rapid screening of Type II PrAMPs is greatly increased through the combination of automated solid-phase peptide synthesis and the single-step reaction to generate the BLI reporter peptides.

To investigate the binding affinity and kinetics of the Pdi1 – ribosome interaction, we immobilized biotinylated wild-type Pdi1 reporter to the streptavidin-coated biosensor. The peptide-functionalized biosensor was exposed to increasing concentrations of ribosome, to a maximum of 1 nM, which resulted in a dose-dependent increase in binding response, indicative of Pdi1-ribosome binding (Figure 3A). The binding affinity and kinetic parameters for this interaction were assayed in three technical replicates and are depicted in Table 2. Remarkably, the average dissociation constant determined for the Pdi1 – ribosome interaction was 209 ± 24 pM, which is > 41000-fold less than what was determined using fluorescence anisotropy. In addition, the Pdi1 – ribosome interaction was determined to have an average dissociation rate of 7.07 × 10−4 ± 1.18 × 10−4 s−1, which suggests that Pdi1 has a residence time in the ribosomal NPET of ~ 24 minutes.

Figure 3: Evaluation of Pdi1 Ribosome Interactions Using Biolayer Interferometry.

Figure 3:

Displayed are representative sensorgrams used to determine binding affinity (Kd) and kinetics (ka and kdis). Assays were performed using ribosome concentrations of 1 nM, 500 pM, 250 pM, 125 pM, 62.5 pM and 31.3 pM. The colors of the individual binding curves refer to the ribosome concentration used as depicted to the right of the sensorgram. Assays were performed in triplicate. (A) Representative sensorgram displaying the binding curves for wild-type Pdi1. (B) Representative sensorgram displaying the binding curves for Pdi1(R19A).

Table 2:

Binding Affinity and Kinetics of Pdil Derivatives

Peptide Kd (pM) ka (1/M*s) kdis (1/s)
Pdi1 Wild-Type 209 3.33E+06 7.07E-04
Pdi1 (R14A) --- --- 3.13e-3*
Pdi1 (P15A) 405 1.62E+06 6.34E-06
Pdi1 (P16A) 514 1.17E+06 5.34E-04
Pdi1 (H17A) 677 1.02E+06 5.34E-04
Pdi1 (P18A) --- --- 1.35e-3*
Pdi1 (R19A) --- --- 1.20e-3*
Pdi1 (L20A) 323 1.55E+06 4.83E-04
Scrambled Pdi1 NBD҂ NBD҂ NBD҂
҂

No Binding Detected

*

Data represents crude values taken from poor curve fitting (R2 < 0.95)

Having established a platform to study the Pdi1-ribosome interaction using BLI, we sought to elucidate the site-specific contributions of the Pdi1 pharmacophore on ribosome binding. We performed an alanine scan of the seven C-terminal residues which contain the highly conserved apidaecin pharmacophore, PHPRL (Table 1). These assays were performed in technical triplicate and revealed that alanine substitutions for peptides Pdi1(P15A), Pdi1(P16A), Pdi1(H17A) and Pdi1(L20A) had minimal impact on their ribosome-binding affinity and interaction kinetics (Table 2 and Supplemental Material). Conversely, Pdi1 derivatives Pdi1(R14A), Pdi1(P18A) and Pdi1(R19A) all displayed distinct binding profiles relative to wild-type Pdi1 (Figure 3B and Supplemental Material), indicative of reduced ribosome binding. Biophysical data for these peptides could not be precisely fitted to kinetics parameters due to poor curve fitting (R2 < 0.95); however, they demonstrated a reduced binding response relative to wild-type Pdi1. Evaluation of crude dissociation rates suggests that these derivatives dissociated from the ribosome at a rate ~2–5× greater than wild-type Pdi1, indicating that they have a reduced residence time in the NPET.

Antibiotic Activity of Pdi1 Derivatives

To validate our BLI results, we first performed a stop-codon read-through assay using drop diffusion to measure the antibiotic activity of select Pdi1 derivatives, as well as their ability to inhibit translation termination (Figure 4).27 To assess mechanism of action, E. coli cells were transformed with a pRXG(UGA) plasmid that encodes genes for red fluorescent protein and green fluorescent protein with an intervening UGA stop codon. Peptides that can inhibit translation termination allow for readthrough of the UGA codon and confer a green, fluorescent halo where the inhibitory peptide has diffused to a sub-inhibitory concentrations.

Figure 4: Drop Diffusion and Stop Codon Readthrough Assay Illustrating PrAMP Antibacterial Activity and Translation Termination Inhibition.

Figure 4:

Drop diffusion test on an agar plate inoculated with the E. coli cells carrying the pRXG(UGA) reporter plasmid. 2 μL droplets of 2 mM solutions of peptides Pdi1, Pdi1(R14A), Pdi1(H17A), Pdi1(P18A), Pdi1(R19A), and PEGylated Pdi1, as well as control peptides ApiIb, Fva1, and Scrambled Pdi1were applied to the plates. Shown is the false-colored image of the plate imaged in the Cy2 channel after overnight incubation at 37 °C.

For this experiment, we examined the Pdi1 derivatives that demonstrated an increased dissociation rate, Pdi1(R14A), Pdi1(P18A), Pdi1(R19A), in contrast with the derivative with the weakest binding affinity, Pdi1(H17A). Given the discrepancy between the Kd calculated for the BLI and fluorescence anisotropy assay, we also synthesized a Pdi1 derivative that contained a 24-unit PEG moiety conjugated to the N-terminus to simulate our BLI reporter peptide (PEGylated Pdi1). We hypothesized that the extended PEG linker could form favorable interactions with the NPET, resulting in the increased apparent binding affinity which may translate to an increase in potency. These peptides were compared to wild-type Pdi1 and a scrambled Pdi1, as well as previously characterized translation termination inhibitor peptides, ApiIb and Fva1.7

The results from the drop diffusion assay demonstrated that an increased dissociation rate and consequent reduced residence time in the ribosomal NPET is a greater indicator of diminished antibiotic activity than binding affinity alone. Specifically, Pdi1(R14A), Pdi1(P18A), and Pdi1(R19A), demonstrated minimal to negligible zones of clearance, whereas Pdi1(H17A) exhibits a pronounced antibiotic effect based on its zone of clearance, albeit to a lesser extent than Pdi1. Notably, the PEGylated Pdi1 derivative demonstrated diminished antibiotic activity, as evidenced by a small zone of clearance; however, this result could be the result of poor compound recognition and intracellular transport by the SbmA transporter. As expected, the positive control wild-type peptides exhibited the greatest antibiotic activity, with Fva1 and Pdi1 displaying a greater zone of clearance than ApiIb. All three positive control peptides also demonstrated translation termination inhibition, as evidenced by induction of the green, fluorescent halo around their zones of clearance. Interestingly, the Pdi1 derivative Pdi1(H17A) failed to produce a fluorescent halo around its zone of clearance which indicates failure to inhibit translation termination to an appreciable degree at sub-inhibitory concentrations.

We also determined the MICs of the peptides by a liquid broth microdilution assay using the outlined Pdi1 derivatives to further assess the impact of pharmacophoric substitutions on antibiotic activity (Table 3). The MIC results confirm the potency of Pdi1 which is nearly 5× more potent than ApiIb7 and roughly equipotent to the synthetic derivative Api137. The PEGylated Pdi1 derivative displayed reduced antibiotic activity with an MIC of 25 μM, which is in line with our drop-diffusion results; however, these results indicate that heavy PEGylation of Pdi1 does not wholly eliminate its antibiotic effect as evidenced by a 4-fold MIC difference between PEGylated Pdi1 and the scrambled Pdi1 negative control peptide. The MIC values for the Pdi1 derivatives also revealed that replacement of the cationic arginine residues in derivatives Pdi1(R14A) and Pdi1(R19A) results in a drastic loss in potency (41-fold and >1333-fold loss respectively). Interestingly, the 0.35 μM MIC determined for Pdi1(P18A) deviated from the drop diffusion results and was comparable to the 0.75 μM MIC of Pdi1(H17A) despite a pronounced difference in their zone of clearance.

Table 3:

Minimum Inhibitory Values of Assayed PrAMPs

Peptide MIC (μM)
Api1b 0.35
Api137 ≤ 0.075
Pdi1 0.075
Pdi1 (R14A) 3.1
Pdi1 (H17A) 0.75
Pdi1 (P18A) 0.35
Pdi1 (R19A) >100
PEGylated Pdi1 25
Scrambled Pdi1 100

Evaluation of Ribosome Stalling for Pdi1 Derivatives

To further elucidate the mechanism of action of Pdi1 derivatives, we performed a toeprinting assay to assess their ability to stall actively translating ribosomes at a stop codon.6 Briefly, in vitro translation was executed in the presence of Pdi1 derivatives, after which reverse transcription was performed and the resulting cDNA fragments were resolved via gel electrophoresis. For this approach, we selected Pdi1(H17A), as it failed to produce a fluorescent halo in the drop diffusion assay, as well as Pdi1(R19A), because the penultimate arginine residue is hypothesized to form a necessary contact with RFs, as shown previously for ApiIb.14 We also tested the PEGylated Pdi1 derivative as well as FITC-Pdi1 to determine whether chemical differences between reporter peptides may have an impact on their mechanism of action and account for the binding affinity differences between the two assays (Figure 5).

Figure 5: In vitro Toeprinting Assay Demonstrating the Ability of Pdi1 Derivatives to Stall Ribosomes at a Model Gene Stop Codon.

Figure 5:

Toeprint bands corresponding to ribosomes arrested at the stop codon is marked with a red arrow. The black arrow indicates the start codon. Lanes are marked according to the Pdi1 derivative added to the cell-free transcription-translation reactions. The lanes marked as ‘No Peptide’ represent control samples where the cell-free transcription–translation reaction was performed in the absence of any PrAMP. The sequence of the modified E. coli yrbA gene and the encoded protein sequence is shown on the left. Sequencing lanes are labeled as C, U, A, G. The dotted line to the right of ‘FITC-Pdi1’ denotes removed gel lanes that contained unrelated samples.

Our toeprinting results confirm the ability of wild-type Pdi1 to stall the ribosome at the mRNA stop codon, as demonstrated previously.7 Interestingly, both reporter peptides demonstrated ribosome stalling, albeit to different extents based on the intensity of the cDNA bands. This result suggests that chemical modifications to native Pdi1 impact ribosome stalling; however, both peptides can coordinate the translation termination complex which fails to account for differences in binding affinity. Also of note, both Pdi1(H17A) and Pdi1(R19A) fail to stall the ribosome at the stop codon, which suggests that both peptides lack translation-termination inhibition. Although the penultimate arginine of the apidaecin pharmacophore (PHPRL) is known to be essential for trapping RFs,6,14 we show that the conserved histidine in the apidaecin pharmacophore is also required for translation termination inhibition of Pdi1.

Discussion

To date, fluorescence anisotropy represents the standard in vitro technique to study the apidaecin-ribosome interaction; however, discrepancies exist between reported binding affinity values and MICs. It has been shown that fluorescein labelling of designer peptides Api88 and Api137 decreases their E. coli MICs 15- and 30-fold respectively, despite a modest impact on their cellular penetration.28 These findings suggest that the decrease in MIC is the result of reduced intracellular activity which could reflect reduced apidaecin-ribosome binding. In addition, the > 50-fold difference between the determined Api137 MIC and the recently reported Kd (Ref. 18) implies Api137 must achieve an intracellular concentration which greatly exceeds their MICs to achieve 50% occupancy of the ribosome binding site. Our toeprinting assay results demonstrate that FITC-Pdi1 retains its ability to inhibit translation termination; however, these assays are performed with peptide concentrations of 50 μM which is substantially greater than the concentration used to perform fluorescence anisotropy experiments.

The BLI platform described in this report represents an orthogonal approach that can be used to study the PrAMP-ribosome interaction and provides the first insight into the interaction kinetics. In contrast to fluorescence anisotropy, which requires micromolar concentrations of ribosomes, our BLI assay was performed with a maximal ribosome concentration of 1 nM, demonstrating the resource-conservative nature and increased throughput of our approach. Interestingly, the Pdi1-ribosome sensorgrams do not present “shark-fin” binding curves which are commonly observed for rapidly dissociating interactions; however similar sensorgram profiles have been reported for slow dissociating interactions such as antibody/antigen pairs.29,30 The results from the BLI assay suggest that Pdi1 binds the ribosome with a ~ 200 pM binding affinity, which is predominantly influenced by a slow dissociation rate; an observation that fits in well with the mechanism of action for Type II PrAMPs. An assumption of the translation termination inhibition model is a long residence time, as the depletion of cellular RF requires Type II PrAMPs to stabilize the translation termination complex over an extended period.

To ensure the peptides could reach and penetrate the ribosomal NPET without interference from the biosensor, the Pdi1 reporter peptides used in the BLI assay were functionalized with a hydrophilic 24-unit PEG linker. The NPET is decorated with rRNA nucleotides which could form favorable intermolecular interactions with the reporter peptide linker. As such, the picomolar binding affinity determined using our BLI approach likely represents the combinatorial effect of native Pdi1 – ribosome interactions and non-native interactions with the linker. For this reason, the binding affinity and kinetics data may not reflect unfunctionalized Pdi1 binding; nonetheless, comparison of assay data for Pdi1 derivatives provides meaningful insight into ribosome binding, as all reporter peptides are functionalized with the same linker. Although structural data are lacking to confirm binding of our surface-bound reporter peptide at the mechanistically relevant NPET site, ribosome stalling induced by PEGylated Pdi1 supports its ability to coordinate the translation termination complex at this site.

Our binding data for the alanine scan of the Pdi1 C-terminus revealed that replacement of residues Arg14, Pro18 and Arg19 had an impact on ribosome binding, specifically by increasing their dissociation rate. Arg19 is a crucial amino acid in Type II PrAMPs, and our toeprinting assay results demonstrate its necessity for translation-termination inhibition. These findings were further validated in cell-based studies where these derivatives exhibited a drastically reduced zone-of clearance in drop diffusion assays and decreased MICs in the range of 5- to >1333-fold relative to Pdi1. The BLI assay was performed in the absence of RF and tRNA; thus, these data suggest that Arg19, as well as Arg14 and Pro18, play a role in ribosome recognition and potentially navigation of the NPET. The penultimate residue, Arg19, is known to be essential for binding to RF,6 but its contribution to ribosome binding is less clear. These results are similar to previous alanine scan experiments with Api137, where replacement of analogous residues resulted in an ≥ 8-fold increase in MIC.13 In the case of Arg14 and Arg19, the replacement of these cationic residues likely disrupts the electrostatic complementarity with the highly anionic ribosome which could impede their ability to navigate the NPET and reduce their residence time. Similarly, while Pro18 does not possess cationic character, proline has a restricted φ angle and a lower barrier between cis and trans conformers; thus, substitution of this residue may impact the conformation of the amino acids, such as Arg19, that are up- and down-stream of this position, which could disrupt the native conformation required to effectively bind the ribosome.

An additional finding from our interrogation of the Pdi1 pharmacophore was the role of His17 in the antibacterial mechanism of action. Our BLI results suggest that substitution of His17 resulted in a 3-fold reduction in ribosome binding affinity; however, unlike the aforementioned derivatives, this derivative presented the canonical binding profile. The results from our drop diffusion assay revealed that Pdi1(H17A) demonstrated significant antibacterial activity compared to other derivatives based on the size of the zone-of-clearance; however, the lack of fluorescent halo suggests an absence of translation-termination inhibition. This observation was confirmed in our toeprinting assay, where Pdi1(H17A) was unable to stall the ribosome at the mRNA stop codon, which also suggests this peptide is not a translation-termination inhibitor. These findings are remarkable, considering the sub-micromolar MIC that was determined for this derivative and suggest an additional mechanism of action is responsible for the potency of Pdi1(H17A). Aapidaecins have been reported to interact with the bacterial chaperone DnaK,12,13 which may account for a portion of the antibacterial activity of Pdi1(H17A). Recent research has also demonstrated that apidaecins bind multiple sites on the 70S ribosome,19,31 with one of these additional binding sites being linked to disruption of 50S subunit assembly and misfolding. Given our BLI data, which suggests that Pdi1(H17A) retains a high affinity for the bacterial ribosome, it is possible that this derivative may compensate for its lack of translation termination inhibition by disrupting ribosome assembly. Although further study is required to elucidate why Pdi1(H17A) retains a sub-micromolar MIC despite a lack of translation termination inhibition, it is evident that this peptide acts through an alternate mechanism of action.

To our knowledge, this study represents the first structure-activity relationship for the antimicrobial peptide Pdi1. Similar to the findings of Huang et al. (Ref. 7), ApiIb was found to have an MIC 4.7-fold greater than Pdi1; however, we present the first comparison of Pdi1 to the synthetically optimized apidaecin, Api137. These results show that Pdi1 and Api137 demonstrate comparable MICs. In the context of insect-derived Type II PRAMPs, the biophysical characterization and ribosome stalling experiments reported here further emphasize the necessity of the C-terminal ‘PHPRL’ and suggest that the nuanced positioning of select residues in the Pdi1 pharmacophore are essential for their antibiotic activity. Another apidaecin identified from Frieseomelitta varia, Fva1, possesses superior antibiotic activity compared to Pdi1 (4-fold) and Api137 (16-fold) when assayed in biologically relevant RPMI/Serum broth.7 Taken together, these results suggest that careful derivatization of the natural product peptides Pdi1 and Fva1 may yield synthetic peptides with augmented antibiotic potential relative to Api137.

Supplementary Material

Supplemental Information

Supporting Information

Additional fluorescence polarization experimental data, reporter peptide synthesis scheme and purity analysis of assayed peptides.

Acknowledgments

This work was supported by the National Institute of Allergy and Infectious Diseases (1 R01 AI162961), the ACS MEDI Predoctoral Fellowship and the University of Illinois Chicago Award for Graduate Research and Undergraduate Research Grant. The authors are grateful to Maxim Svetlov, Shura Mankin, and Nora Vázquez-Laslop, University of Illinois Chicago, as well as Degang Liu, Sartorius, for helpful insight and discussions.

References

  • 1.Llor C, Bjerrum L. 2014. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 5:229–241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Prestinaci F, Pezzotti P, Pantosti A. 2015. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109:309–318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Antimicrobial Resistance Collaborators. 2024. The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis. Lancet Glob Health 12:e201–e216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kim H-J, Na SW, Alodaini HA, Al-Dosary MA, Nandhakumari P, Dyona L. 2021. Prevalence of multidrug-resistant bacteria associated with polymicrobial infections. J Infect Public Health 14:1864–1869. [DOI] [PubMed] [Google Scholar]
  • 5.Lei T-Y, Liao B-B, Yang L-R, Wang Y, Chen X-B. 2024. Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat. Microbiol Res 288:127839. [DOI] [PubMed] [Google Scholar]
  • 6.Florin T, Maracci C, Graf M, Karki P, Klepacki D, Berninghausen O, Beckmann R, Vázquez-Laslop N, Wilson DN, Rodnina MV, Mankin AS. 2017. An antimicrobial peptide that inhibits translation by trapping release factors on the ribosome. Nat Struct Mol Biol 24:752–757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang W, Baliga C, Aleksandrova EV, Atkinson G, Polikanov YS, Vázquez-Laslop N, Mankin AS. 2024. Activity, structure, and diversity of Type II proline-rich antimicrobial peptides from insects. EMBO Rep 25:5194–5211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Magana M, Pushpanathan M, Santos AL, Leanse L, Fernandez M, Ioannidis A, Giulianotti MA, Apidianakis Y, Bradfute S, Ferguson AL, Cherkasov A, Seleem MN, Pinilla C, de la Fuente-Nunez C, Lazaridis T, Dai T, Houghten RA, Hancock REW, Tegos GP. 2020. The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis 20:e216–e230. [DOI] [PubMed] [Google Scholar]
  • 9.Mattiuzzo M, Bandiera A, Gennaro R, Benincasa M, Pacor S, Antcheva N, Scocchi M. 2007. Role of the Escherichia coli SbmA in the antimicrobial activity of proline-rich peptides. Mol Microbiol 66:151–163. [DOI] [PubMed] [Google Scholar]
  • 10.Schmidt A, Kochanowski K, Vedelaar S, Ahrné E, Volkmer B, Callipo L, Knoops K, Bauer M, Aebersold R, Heinemann M. 2016. The quantitative and condition-dependent Escherichia coli proteome. Nat Biotechnol 34:104–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Skowron KJ, Baliga C, Johnson T, Kremiller KM, Castroverde A, Dean TT, Allen AC, Lopez-Hernandez AM, Aleksandrova EV, Klepacki D, Mankin AS, Polikanov YS, Moore TW. 2023. Structure-Activity Relationships of the Antimicrobial Peptide Natural Product Apidaecin. J Med Chem 66:11831–11842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Czihal P, Knappe D, Fritsche S, Zahn M, Berthold N, Piantavigna S, Müller U, Van Dorpe S, Herth N, Binas A, Köhler G, De Spiegeleer B, Martin LL, Nolte O, Sträter N, Alber G, Hoffmann R. 2012. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens. ACS Chem Biol 7:1281–1291. [DOI] [PubMed] [Google Scholar]
  • 13.Berthold N, Czihal P, Fritsche S, Sauer U, Schiffer G, Knappe D, Alber G, Hoffmann R. 2013. Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens. Antimicrob Agents Chemother 57:402–409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Baliga C, Brown TJ, Florin T, Colon S, Shah V, Skowron KJ, Kefi A, Szal T, Klepacki D, Moore TW, Vázquez-Laslop N, Mankin AS. 2021. Charting the sequence-activity landscape of peptide inhibitors of translation termination. Proc Natl Acad Sci U S A 118:e2026465118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.El-Faham A, Al Marhoon Z, Abdel-Megeed A, Albericio F. 2013. OxymaPure/DIC: an efficient reagent for the synthesis of a novel series of 4-[2-(2-acetylaminophenyl)-2-oxo-acetylamino] benzoyl amino acid ester derivatives. Molecules 18:14747–14759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jullian M, Hernandez A, Maurras A, Puget K, Amblard M, Martinez J, Subra G. 2009. N-terminus FITC labeling of peptides on solid support: the truth behind the spacer. Tetrahedron Letters 50:260–263. [Google Scholar]
  • 17.Ohashi H; Shimizu Y; Ying B-W; Ueda T Efficient Protein Selection Based on Ribosome Display System with Purified Components. Biochem Biophys Res Commun 2007, 352 (1), 270–276. [DOI] [PubMed] [Google Scholar]
  • 18.Ludwig T, Krizsan A, Mohammed GK, Hoffmann R. 2022. Antimicrobial Activity and 70S Ribosome Binding of Apidaecin-Derived Api805 with Increased Bacterial Uptake Rate. Antibiotics (Basel) 11:430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lauer SM, Reepmeyer M, Berendes O, Klepacki D, Gasse J, Gabrielli S, Grubmüller H, Bock LV, Krizsan A, Nikolay R, Spahn CMT, Hoffmann R. 2024. Multimodal binding and inhibition of bacterial ribosomes by the antimicrobial peptides Api137 and Api88. Nat Commun 15:3945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, Ueda T. 2001. Cell-free translation reconstituted with purified components. Nat Biotechnol 19:751–755. [DOI] [PubMed] [Google Scholar]
  • 21.Krizsan A, Volke D, Weinert S, Sträter N, Knappe D, Hoffmann R. 2014. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angew Chem Int Ed Engl 53:12236–12239. [DOI] [PubMed] [Google Scholar]
  • 22.Brakel A; Krizsan A; Itzenga R; Kraus CN; Otvos L; Hoffmann R Influence of Substitutions in the Binding Motif of Proline-Rich Antimicrobial Peptide ARV-1502 on 70S Ribosome Binding and Antimicrobial Activity. Int J Mol Sci 2022, 23 (6), 3150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Davoodi S, Daryaee F, Chang A, Walker SG, Tonge PJ. 2020. Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability. ACS Infect Dis 6:629–636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Svetlov MS, Vázquez-Laslop N, Mankin AS. 2017. Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics. Proc Natl Acad Sci U S A 114:13673–13678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pandiarajan I, Walunj SB, Banerjee N, Rout J, Srivastava S, Patankar S, Kaledhonkar S. 2024. Application of bio-layer interferometry for the analysis of ribosome-protein interactions. Front Mol Biosci 11:1398964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Oesterhelt F, Rief M, Gaub HE. 1999. Single molecule force spectroscopy by AFM indicates helical structure of poly(ethylene-glycol) in water. New J Phys 1:6–6. [Google Scholar]
  • 27.Mangano K, Klepacki D, Ohanmu I, Baliga C, Huang W, Brakel A, Krizsan A, Polikanov YS, Hoffmann R, Vázquez-Laslop N, Mankin AS. 2023. Inhibition of translation termination by the antimicrobial peptide Drosocin. Nat Chem Biol 19:1082–1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Berthold N, Hoffmann R. 2014. Cellular uptake of apidaecin 1b and related analogs in Gram-negative bacteria reveals novel antibacterial mechanism for proline-rich antimicrobial peptides. Protein Pept Lett 21:391–398. [DOI] [PubMed] [Google Scholar]
  • 29.Kumaraswamy S; Tobias R Label-Free Kinetic Analysis of an Antibody-Antigen Interaction Using Biolayer Interferometry. Methods Mol Biol 2015, 1278, 165–182. [DOI] [PubMed] [Google Scholar]
  • 30.Kamat V; Rafique A Designing Binding Kinetic Assay on the Bio-Layer Interferometry (BLI) Biosensor to Characterize Antibody-Antigen Interactions. Anal Biochem 2017, 536, 16–31. [DOI] [PubMed] [Google Scholar]
  • 31.Lauer SM, Gasse J, Krizsan A, Reepmeyer M, Sprink T, Nikolay R, Spahn CMT, Hoffmann R. 2025. The proline-rich antimicrobial peptide Api137 disrupts large ribosomal subunit assembly and induces misfolding. Nat Commun 16:567. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Information

RESOURCES